|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | Can Hybrid SPECT-CT Overcome the Limitations Associated With Poor Imaging Properties of 131I-MIBG?: Comparison With Planar Scintigraphy and SPECT in Pheochromocytoma显示文摘 | Punit Sharma Varun Singh Dhull Sunil Jeph Rama Mohan Reddy Harmandeep Singh Niraj Naswa Chandrasekhar Bal Rakesh Kumar | 2013 | Clinical Nuclear Medicine2013，，： | 1 |
| 2 | Feasibility and efficacy of delayed pharmacoinvasive therapy for STelevation myocardial infarction显示文摘BACKGROUND ST-elevation myocardial infarction(STEMI)refers to a clinical syndrome that features symptoms of myocardial ischemia with consequent ST-elevation on electrocardiography and an associated rise in cardiac biomarkers.Rapid restoration of brisk flow in the coronary vasculature is critical in reducing mortality and morbidity.In patients with STEMI who could not receive primary percutaneous coronary intervention(PCI)on time,pharmacoinvasive strategy(thrombolysis followed by timely PCI within 3-24 h of its initiation)is an effective option.AIM To analyze the role of delayed pharmacoinvasive strategy in the window period of 24-72 h after thrombolysis.METHODS This was a physician-initiated,single-center prospective registry between January 2017 and July 2017 which enrolled 337 acute STEMI patients with partially occluded coronary arteries.Patients received routine pharmacoinvasive therapy(PCI within 3-24 h of thrombolysis)in one group and delayed pharmacoinvasive therapy(PCI within 24-72 h of thrombolysis)in another group.The primary endpoint was major adverse cardiac and cerebrovascular events(MACCE)within 30 d of the procedure.The secondary endpoints included major bleeding as defined by Bleeding Academic Research Consortium classification,angina,and dyspnea within 30 d.RESULTS The mean age in the two groups was comparable(55.1±10.1 years vs 54.2±10.5 years,P=0.426).Diabetes was present among 20.2%and 22.1%of patients in the routine and delayed groups,respectively.Smoking rate was 54.6%and 55.8%in the routine and delayed groups,respectively.Thrombolysis was initiated within 6 h of onset of symptoms in both groups(P=0.125).The mean time from thrombolysis to PCI in the routine and delayed groups was 16.9±5.3 h and 44.1±14.7 h,respectively.No significant difference was found for the occurrence of measured clinical outcomes in the two groups within 30 d(8.7%vs 12.9%,P=0.152).Univariate analysis of demographic characteristics and risk factors for patients who reported MACCE in the two groups did not demonstrate any significant correlation.Secondary endpoints such as angina,dyspnea,and major bleeding were non-significantly different between the two groups.CONCLUSION Delayed PCI pharmacoinvasive strategy in a critical diseased but not completely occluded artery beyond 24 h in patients who have been timely thrombolyzed seems a reasonable strategy. | Rishi Sethi Lalit Mohan Pravesh Vishwakarma Abhishek Singh Swati Sharma Monika Bhandari Ayush Shukla Akhil Sharma Gaurav Chaudhary Akshyaya Pradhan Sharad Chandra Varun Shankar Narain Sudhanshu Kumar Dwivedi | 2023 | World Journal of Cardiology2023，15，1： | 1 |
| 3 | Relevance of Helicobacter pylori genotypes in gastric pathology and its association with plasma malondialdehyde and nitric oxide levels显示文摘 | Santosh K. Tiwari G. Manoj Vishwas Sharma G. Sivaram R. Saikant Avinash Bardia Varun K. Sharma Zakia Abid Aleem A. Khan M. Aejaz Habeeb C. M. Habibullah B. Santhosh Kumar Amrita Nandan | 2010 | Inflammopharmacology2010，，2： | 1 |
| 4 | One Week of Nitrofurantoin Before Percutaneous Nephrolithotomy Significantly Reduces Upper Tract Infection and Urosepsis: A Prospective Controlled Study显示文摘 | Sanand Bag Santosh Kumar Neelam Taneja Varun Sharma Arup K. Mandal Shrawan K. Singh | 2011 | Urology2011，，1： | 1 |
| 5 | Restoration of established systemic inflammation and autoimmunity by Foxp3^(+) regulatory T cells显示文摘Immune tolerance ensures the disease-free status of an individual by preventing the appearance of pathological conditions,such as autoimmune and inflammatory diseases.Among the various players implicated in the maintenance of immune tolerance,CD4^(+)CD25^(+)regulatory T(Treg)cells that express the X-linked transcription factor Forkhead box P3(Foxp3)play a major role.FoxP3 governs the functions of Treg cells.In fact,a deficiency in Treg cells due to mutations in FoxP3 leads to fatal autoimmune and inflammatory conditions in humans called immunodysregulation polyendocrinopathy enteropathy x-linked(IPEX)syndrome.Similar observations have also been made in mice,in which FoxP3 deficiency leads to autoimmune pathology and death early in life.In addition,various mutations in Treg-associated immunoregulatory molecules lead to inflammatory conditions[1]. | Varun Kumar Sharma Jagadeesh Bayry | 2022 | Cellular & Molecular Immunology2022，19，2： | 0 |
| 6 | Using focused pharmacovigilance for ensuring patient safety against antileishmanial drugs in Bangladesh’s National Kala-azar Elimination Programme显示文摘Background:Adverse effects of antileishmanial drugs can affect patients’quality of life and adherence to therapy for visceral leishmaniasis(VL)and post-kala-azar dermal leishmaniasis(PKDL).In Bangladesh,there are 26 treatment centers that manage leishmaniasis cases coming from 100 endemic upazilas(subdistricts)of 26 districts(these include VL,PKDL,treatment failure,and relapse VL and cutaneous leishmaniasis cases).This study aimed to investigate the feasibility of using focused pharmacovigilance for VL(VLPV)in Bangladesh’s National Kala-azar Elimination Programme for the early detection and prevention of expected and unexpected adverse drug reactions(ADRs).Methods:This activity has been going on since December 2014.Activity area includes secondary public hospital or Upazila health complex(UHC)in hundred sub districts and Surya Kanta Kala-azar Research Center(SKKRC)in Mymensingh District,a specialized center for management of complicated VL and PKDL cases.Communicable Disease Control(CDC)of the Directorate General of Health Services(DGHS)assigned twenty five of hundred UHCs and SKKRC(total 26)as treatment centers depending on their suitable geographical location.This was implemented for better management of VL cases with Liposomal Amphotericin B(AmBisome®)to ensure patient convenience and proper utilization of this expensive donated drug.A VLPV expert committee and a UHC VLPV team were established,an operational manual and pharmacovigilance report forms were developed,training and refresher training of health personnel took place at UHCs and at the central level,collected information such as patient data including demographics,treatment history and response,adverse events were analyzed.This report includes information for the period from December 2014 to December 2016.Results:From December 2014 to December 2016,1327 leishmaniasis patients were treated and 1066(80%)were available for VLPV.Out of these,57,33,9,and 1%were new VL,PKDL,VL relapse,and other cases,respectively.Liposomal amphotericin B was mostly used(82%)for case management,followed by miltefosine(20%)and paromomycin(3%).Out of the 1066 patients,26%experienced ADRs.The most frequent ADR was fever(17%,176/1066),followed by vomiting(5%,51/1066).Thirteen serious adverse events(SAEs)(eight deaths and five unexpected SAEs)were observed.The expert committee assessed that three of the deaths and all unexpected SAEs were possibly related to treatment.Out of the five unexpected SAEs,four were miltefosine-induced ophthalmic complications and the other was an AmBisome^(■)-induced avascular necrosis of the nasal alae.The Directorate General of the Drug Administration entered the ADRs into the World Health Organization Uppsala Monitoring Centre(WHO-UMC)VigiFlow database.Conclusions:This study found that VLPV through NKEP is feasible and should be continued as a routine activity into the public health system of Bangladesh to ensure patient safety against anti-leishmanial drugs. | Md.Sakhawat Hossain Amresh Kumar A.F.M Akhtar Hossain Md.Mahshin Abhijit Sharma Md.Akter Hossain Varun Sharma Rashidul Haque A.K.M Shamsuzzaman Shomik Maruf Prakash Ghosh Vivek Ahuja Dinesh Mondal | 2018 | Infectious Diseases of Poverty2018，7，1： | 0 |
您所在的机构暂未开通此部分的功能，请联系管理员